|
|
 Previous Article | Table of Contents | Next Article 
Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on
hematopoietic regeneration as demonstrated in a nonhuman primate
chemotherapy model
EF Winton, J Srinivasiah, BK Kim, CD Hillyer, EA Strobert, JL Orkin, RB Swenson, HM McClure, LA Myers and R Saral
Emory University School of Medicine, Atlanta, GA.
Using a recently developed hepsulfam-induced pancytopenia model in rhesus
macaques, we have studied the effects of recombinant human interleukin-6
(rhIL-6) and rhIL-3 on marrow regeneration. Control animals were given
hepsulfam (1.5 g/m2 by a single 30-minute intravenous [i.v.] injection, n =
4), while study animals received hepsulfam followed by rhIL-6, rhIL-3, or a
combination of rhIL-6 and rhIL-3 (n = 3 per study group). Each cytokine was
administered by once- daily subcutaneous (SC) injection (15
micrograms/kg/d) for 3 weeks beginning the day after chemotherapy (days 2
through 22). Mean platelet counts in control animals were <
100,000/microL on days 15 through 24, with 50% of the counts <
50,000/microL and two of four animals requiring platelet transfusion. In
the rhIL-6- and rhIL-6/rhIL-3- treated groups, the nadir mean platelet
counts were 164,000 +/- 58,700/microL and 162,300 +/- 23,800/microL,
respectively, and occurred on day 15. Platelet counts in the rhIL-3-treated
group were similar to those in controls. Mean absolute neutrophil counts
(ANCs) < 1,000/microL occurred on days 10 through 29 in control animals,
days 8 through 15 in rhIL-6-treated animals, and days 6 through 8 and 13 in
rhIL-6/rhIL-3-treated animals. The frequency of ANCs < 500/microL was
significantly less in the rhIL-6- and rhIL-6/rhIL-3-treated groups versus
control groups (2.7 +/- 0.6 and 2.0 +/- 1.0 vs 7.0 +/- 1.4 occurrences,
respectively; P < .05). rhIL-3-treated animals had ANCs similar to those
in controls; one animal died with septicemia on day 21. Monkeys receiving
rhIL-6 were significantly more anemic during the cytokine administration
period; however, the anemia resolved by day 24. Coadministration of rhIL-3
and rhIL-6 partially corrected the anemia. The data indicate that rhIL-6
prevents significant thrombocytopenia and shortens the neutropenic period
in this chemotherapy model.
Volume 84,
Issue 1,
pp. 65-73,
07/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. M. Farese, D. B. Casey, W. G. Smith, R. M. Vigneulle, J. P. McKearn, and T. J. MacVittie
Leridistim, a Chimeric Dual G-CSF and IL-3 Receptor Agonist, Enhances Multilineage Hematopoietic Recovery in a Nonhuman Primate Model of Radiation-Induced Myelosuppression: Effect of Schedule, Dose, and Route of Administration
Stem Cells,
November 1, 2001;
19(6):
522 - 533.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Bracho, M. D. Krailo, V. Shen, S. Bergeron, V. Davenport, W. Liu-Mares, B. R. Blazar, A. Panoskaltsis-Mortari, C. van de Ven, R. Secola, et al.
A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities
Clin. Cancer Res.,
January 1, 2001;
7(1):
58 - 67.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. J. MacVittie, A. M. Farese, W. G. Smith, C. M. Baum, E. Burton, and J. P. McKearn
Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression
Blood,
February 1, 2000;
95(3):
837 - 845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Wagemaker, K. J. Neelis, S. C.C. Hartong, A. W. Wognum, G. R. Thomas, P. J. Fielder, and D. L. Eaton
The Efficacy of Recombinant Thrombopoietin in Murine and Nonhuman Primate Models for Radiation-Induced Myelosuppression and Stem Cell Transplantation
Stem Cells,
November 1, 1998;
16(6):
375 - 386.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. A. Harker, U. M. Marzec, A. B. Kelly, E. Cheung, A. Tomer, J. L. Nichol, S. R. Hanson, and R. B. Stead
Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor
Blood,
January 1, 1997;
89(1):
155 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Schlerman, A. Bree, M. Kaviani, S. Nagle, L. Donnelly, L. Mason, R. Schaub, S. Grupp, and S. Goldman
Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates
Stem Cells,
September 1, 1996;
14(5):
517 - 532.
[Abstract]
|
|
|
|
|
